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ABSTRACT
Objective Treatment with peginterferon a-2a (PegIFN)
for 48 weeks is the standard of care for selected HBeAg-
negative patients chronically infected with hepatitis B
virus (HBV), but with limited treatment efficacy. A study
was undertaken to investigate whether treatment
extension to 96 weeks improves the outcome in this
patient population.
Methods 128 HBeAg-negative patients (120 genotype D)
were randomised to weekly 180 mg PegIFN for 48 weeks
(group A, n¼51), 180 mg PegIFN for 48 weeks followed
by 135 mg weekly for an additional 48 weeks (group B,
n¼52) or 180 mg PegIFN plus lamivudine (100 mg/day)
for 48 weeks then 135 mg PegIFN for 48 weeks (group
C, n¼25). Endpoints were alanine aminotransferase
normalisation plus HBV DNA <3400 IU/ml (primary),
HBV DNA <2000 IU/ml and HBsAg clearance at
48 weeks after treatment.
Results Forty-eight weeks after treatment, six patients
in group A and 13 in group B achieved alanine
aminotransferase normalisation plus HBV DNA
<3400 IU/ml (11.8% vs 25.0%, p¼0.08), 6 vs 15
patients had HBV DNA <2000 IU/ml (11.8% vs 28.8%,
p¼0.03), 0 vs 3 achieved HBsAg clearance (0% vs 5.8%,
p¼0.24) and 0 vs 5 had HBsAg <10 IU/ml (0% vs 9.6%,
p¼0.06). While extended PegIFN treatment was the
strongest independent predictor of response, the
combination with lamivudine did not improve responses.
Discontinuation rates were similar among the groups
(19.6%, 23.1%, 32.0%, p¼0.81) and were mostly due to
PegIFN-related adverse events.
Conclusions In HBeAg-negative genotype D patients
with chronic hepatitis B, PegIFN treatment for 96 weeks
was well tolerated and the post-treatment virological
response improved significantly compared with
48 weeks of treatment.
Trial registration number http://ClinicalTrials.gov
registration number: NCT01095835.
INTRODUCTION
The hepatitis B virus (HBV) is a leading cause of
morbidity and anticipated liver-related death, with
approximately 400 million persons being chroni-
cally infected worldwide.1e3 The lethal conse-
quences of HBVare more common in patients with
HBeAg-negative hepatitis, which represents the
late phase of HBV infection, predominates in
the Mediterranean basin and is expected to become
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Significance of this study
What is already known on this subject?
< HBeAg-negative chronic hepatitis B carries
a significant risk of progression to cirrhosis,
liver cancer and anticipated liver-related death.
Long-term nucleos(t)ide therapy and, in selected
patients, 48-week administration of pegylated-
interferon (PegIFN) may attenuate progression
of hepatitis B.
< Compared with nucleos(t)ide therapy, PegIFN
a-2a causes higher rates of sustained virological
response accompanied by HBsAg seroclearance
in a subset of patients.
< HBeAg-negative patients with genotype D infec-
tion are more resistant to PegIFN than other
genotypes due to the higher rates of hepatitis
relapse in the first year of post-treatment follow-
up. They have experienced higher rates of
sustained responses to standard interferon
administered for >48 weeks which reduced the
rates of post-treatment hepatitis relapse.
What are the new findings?
< PegIFN 180 mg weekly for 48 weeks followed
by 135 mg for an additional 48 weeks caused
more virological responses (HBV DNA
<2000 IU/ml: 28.8% vs 11.8%, p¼0.03) and
higher post-treatment rates of HBsAg <10 IU/ml
(9.6% vs 0%, p¼0.06) than weekly PegIFN
180 mg given for 48 weeks.
< Extended PegIFN treatment was well tolerated
and discontinuation rates were similar to those
with the 48-week standard of care.
How might it impact on clinical practice in the
foreseeable future?
< HBeAg-negative genotype D patients with
chronic hepatitis B may benefit in the long
term from 96 weeks of PegIFN therapy.
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the dominant HBV disease pattern worldwide in future
years.2e4 Since persistent suppression of the virus is the only
therapeutic option available to stop progression of this infection
towards end-stage liver disease and its lethal consequences,2 3
direct antiviral agents like nucleos(t)ide analogues that act by
causing permanent inhibition of HBV replication have gained
popularity as a user-friendly, safe and effective treatment
modality of HBV infection; however, they require life-long
administration.5e7 A limited course of interferon (IFN) may be
a more interesting therapeutic option in selected HBeAg-nega-
tive patients since it may cause off-therapy HBsAg clearance and
seroconversion which represent a proxy to a clinical cure of
hepatitis B.8
Among HBeAg-negative patients, those infected with geno-
type D HBVare common in our regions and are more difﬁcult to
treat successfully with IFN than patients with other genotype-
related hepatitis B, as demonstrated by the higher rates of
hepatitis relapse in the year after treatment compared with
genotype A or B infections.9e11 An early study which demon-
strated improved rates of durable responses in HBeAg-negative
patients with genotype D following 24 months of treatment
with standard IFN as a consequence of reduced rates of post-
treatment hepatitis relapse12 13 opened the way to a recent pilot
study with peginterferon a-2a (PegIFN) administered for
60 weeks.14 This study resulted in higher rates of sustained
response compared with historical controls receiving the stan-
dard 48 weeks of treatment. Whether the combination of direct
antiviral agents with extended IFN therapy has an added value
in improving the therapeutic response of HBeAg-negative
patients with chronic hepatitis B remains to be clariﬁed.8e15
To assess whether 96-week treatment improves the outcome
of PegIFN therapy in this difﬁcult to cure population, we
performed a randomised study which compared the efﬁcacy and
safety of 96-week versus 48-week treatment with PegIFN in
patients predominantly infected with genotype D HBV. An
additional exploratory group of patients treated for 96 weeks, in
whom lamivudine was added to PegIFN during the ﬁrst
48 weeks of treatment, was also included.
METHODS
Study design
This phase IIIB randomised open-label study was conducted in
22 centres in Italy between February 2005 and January 2010
(NCT01095835). At the end of the screening phase, eligible
patients were randomised to one of three treatment groups. The
randomisation list was generated centrally by an independent
biostatistician using the Proc Plan of the SAS System V.8.2.
Patients were assigned in a block randomised design of 25 in
a 10:10:5 ratio to groups A, B and C, respectively. A total of 11
blocks were generated. Group A received PegIFN (Pegasys;
F Hoffmann-La Roche, Basel, Switzerland) 180 mg weekly for
48 weeks, group B received PegIFN 180 mg weekly for 48 weeks
followed by 135 mg weekly for 48 weeks (a total of 96 weeks of
treatment) and group C received PegIFN 180 mg weekly plus
lamivudine (Zefﬁx, GlaxoSmithKline, Brentford, UK) 100 mg
daily for 48 weeks, then PegIFN 135 mg weekly for 48 weeks (a
total of 96 weeks of treatment). The treatment period was
followed by a 1-year (48-week) observation period. Evaluations
were performed at treatment weeks 1, 2, 4, 6, 8, 12, 18, 24, 30,
36, 42 and 48 (all patients). Patients in groups B and C were also
evaluated at treatment weeks 50, 54, 60, 66, 72, 78, 84, 90 and
96. Follow-up assessments were performed at weeks 2, 4, 8, 12,
18, 24 (6 months), 36 (9 months) and 48 (1 year) after treat-
ment. The study was conducted according to the Declaration of
Helsinki and the International Conference on Harmonisation
Consolidated Guideline on Good Clinical Practice.
Patients
Adult patients (18e70 years) with HBeAg-negative chronic
hepatitis B (hepatitis B surface antigen (HBsAg)-positive and
anti-HBs-negative, HBeAg-negative and anti-HBe-positive) for at
least 6 months, HBV DNA levels >17 200 IU/ml (>100 000
copies/ml) and alanine aminotransferase (ALT) levels $1 times
upper limit of normal (ULN) but #10 times ULN during the
screening visit were eligible for inclusion in the study. Patients
were required to have a liver biopsy showing chronic hepatitis B
and Ishak ﬁbrosis score $1 performed within the 24 months
preceding the screening. Patients with a histological diagnosis of
cirrhosis (Ishak ﬁbrosis score 5 or 6) and compensated liver
disease could be included. Exclusion criteria included infection
with hepatitis A virus, hepatitis C virus, hepatitis delta virus or
HIV co-infection; previous treatment with interferon-based
therapy, any anti-HBV nucleoside or nucleotide analogue, anti-
neoplastic or immunomodulatory therapy within the
12 months preceding enrolment; ChildePugh score >6 or
history or other evidence of gastrointestinal bleeding or varices
$grade 2; hepatocellular carcinoma; autoimmune liver disease;
pre-existing severe depression or other psychiatric disease;
signiﬁcant cardiac or renal disease; seizure disorders; severe
retinopathy or any other serious concomitant illnesses; alcohol
or drug abuse.
Measurements
All the biochemical, virological, haematological and immuno-
logical assessments used to include or exclude patients and to
monitor patients during and off therapy were performed in each
centre according to locally validated procedures with the
exclusion of HBV DNA, genotype of HBV and HBsAg levels.
Routine baseline assessments of ALT levels were quantiﬁed at
each centre with the centre’s ULN used as reference. For anal-
ysis, these values were then standardised to the Roche reference
range of 0e55 IU/l, with values#55 IU/l indicating normal ALT.
Serum HBV DNA levels were measured centrally using the
COBAS TaqMan HBV Test (Roche Molecular Diagnostics,
Pleasanton, California, USA; limit of detection 6 IU/ml) at the
Liver Center, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore
Policlinico, University of Milan, Italy. HBV genotypes were
determined by INNO-LiPA HBV genotyping (Innogenetics NV,
Ghent, Belgium). HBsAg levels were quantiﬁed centrally (Abbott
Laboratories, Wiesbaden, Germany) using the Abbott Architect
HBsAg assay (Abbott Ireland Diagnostics Division, Sligo,
Ireland; dynamic range 0.05e250.0 IU/ml) after a 1:150 dilution.
Samples with HBsAg >250.0 IU/ml at this dilution were
retested after a dilution of 1:500. Samples still displaying HBsAg
levels of >250 IU/ml were retested with a ﬁnal dilution of
1:1000. Samples with HBsAg levels <0.05 IU/ml at 1:150 dilu-
tion were retested undiluted.
Efficacy assessments
The efﬁcacy analysis included all patients who received $1 dose
of study medication (intention-to-treat population). The
protocol-deﬁned primary endpoint was a combined response
(ALT normalisation and HBV DNA suppression to <3400 IU/ml
(<20 000 copies/ml)) 48 weeks after treatment. Secondary
and exploratory outcomes included biochemical, virological and
serological efﬁcacy parameters at the end of treatment and
24 weeks and 48 weeks after treatment. These included ALT
normalisation; HBV DNA levels <3400 IU/ml, <2000 IU/ml or
Hepatology
Gut 2013;62:290–298. doi:10.1136/gutjnl-2011-301430 291
 group.bmj.com on May 22, 2013 - Published by gut.bmj.comDownloaded from 
below limit of detection (6 IU/ml); and HBsAg clearance
(<0.05 IU/ml) or HBsAg #10 IU/ml. Patients with missing
values to deﬁne the response were considered as non-responders.
The occurrence of lamivudine resistance was determined in
group C.
Safety assessments
Measures of safety included clinical adverse events (AEs),
haematological measurements, clinical chemical measurements
and vital signs. The analysis of on-treatment AEs included all
AEs reported between the ﬁrst study dose and the end of the ﬁrst
8 weeks of the post-treatment follow-up period.
Statistical methods
The trial was designed as a superiority study to detect clinically
meaningful differences in the rates of the combined response
between groups A and B. Comparison with group C was
exploratory only. The sample size of 95 patients per group was
determined to have a statistical power of 80% of detecting
a signiﬁcant absolute difference of 18% in rates of the combined
response between groups A (18%) and B (36%) when a two-
sided test was employed at the 0.05 signiﬁcance level. The
sample size of group C was ﬁxed at 50% of the sample size of
groups A and B. This resulted in an overall total of 250 patients.
Analyses of efﬁcacy included data from all patients randomised
and who received at least one dose of study medication.
Continuous variables were summarised using descriptive
statistics and discrete variables using number and percentage of
patients. Differences in baseline characteristics between groups
A and B were assessed using the Pearson c2 test for discrete
variables and the two-sided t test or Wilcoxon test for contin-
uous variables. The Pearson c2 test or Fisher exact test (in the
case of cell frequencies <5) was also applied to verify the
hypothesis of the primary and secondary endpoints. The 95% CI
of the difference in response rates between groups was calcu-
lated. No adjustment for multiple testing was adopted.
Logistic regression analyses involving the effect of age, height,
weight, gender, genotype, treatment regimen, baseline ALT level,
baseline HBV DNA level, baseline HBsAg level and presence or
absence of cirrhosis were undertaken to determine if any of these
factors were predictive of the combined response and of the
virological response 1 year after treatment. On-treatment HBV
DNA and HBsAg levels were also tested as predictive factors. All
reported p values were two-sided and the level of signiﬁcance
was set to 0.05.
RESULTS
Patient disposition
The enrolment target of 250 patients was not met and 131
patients were randomised. Of these, 128 received at least one
dose of study treatment and formed the intention-to-treat
population (ﬁgure 1), causing the study power to decline from
the predeﬁned 80% to 55%.
Baseline characteristics
The treatment groups were well balanced with regard to clinical
and virological characteristics at baseline (table 1); 94% of the
patients were infected with HBV genotype D. There were more
men in group B than in groups A and C. A histological activity
index score of 2 was the most frequently reported category in all
groups (45.1% of patients in group A, 36.5% in group B and
40.0% in group C); only 16 patients (12.5%) had cirrhosis (Ishak
score 5/6).
Patients treated with PegIFN (group A vs group B)
On-treatment response
In group A mean6SD (median) HBV DNA levels were 3.562.1
(2.9) log10 IU/ml at week 12, 2.662.0 (1.9) log10 IU/ml at week
24, 2.361.9 (1.8) log10 IU/ml at week 36 and 2.561.9 (1.9) log10
IU/ml at week 48 (ﬁgure 2). A similar decline was observed in
group B (HBV DNA levels of 3.762.0 (3.5) log10 IU/ml, 2.862.2
(1.8) log10 IU/ml, 2.762.3 (1.9) log10 IU/ml and 2.462.2 (1.9)
Figure 1 Patient disposition. Patients
in group A received peginterferon a-2a
180 mg/week for 48 weeks, those in
group B received peginterferon a-2a
180 mg/week for 48 weeks followed by
peginterferon a-2a 135 mg/week for
48 weeks and patients in group C
received peginterferon a-2a 180 mg/
week plus lamivudine 100 mg/day for
48 weeks followed by peginterferon
a-2a 135 mg/week for 48 weeks. AE,
adverse event.
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log10 IU/ml, respectively). During the extended treatment period
in group B (weeks 49e96), mean HBV DNA levels remained
between 2.2 and 2.5 log10 IU/ml (ﬁgure 2). The results of the
individual efﬁcacy parameters at the end of treatment are shown
in table 2.
Post-treatment response
Twenty-four weeks after treatment, 12 patients in group A and
15 in group B had HBV DNA <3400 IU/ml and normal ALT
(23.5% vs 28.8%, p¼0.54). Response rates for the composite
endpoint (HBV DNA <3400 IU/ml and ALT normalisation
48 weeks post-treatment) were 11.8% (6/51) in group A and
25.0% (13/52) in group B (p¼0.08; table 3), causing the study
power to further decline from 55% to 39%.
There were no signiﬁcant differences in the proportions of
patients achieving ALT normalisation between groups A and B
at either the 24-week (45.1% (23/51) and 46.2% (24/52),
respectively; p¼0.91) or 48-week post-treatment assessments
(35.3% (18/51) and 34.6% (18/52), respectively; p¼0.94; table 3).
Seventeen patients (33%) in group A and 16 (31%) in group B
had persistently normal ALT levels up to both 24 and 48 weeks
post-treatment. Mean HBV DNA levels were signiﬁcantly lower
in group B than in group A patients at both time points (2.2 vs
3.4 log10 IU/ml at week 24, p¼0.0082; 2.4 vs 3.6 log10 IU/ml at
week 48, p¼0.0103).
Using the 3400 IU/ml cut-off, virological response rates
between groups A and B were not signiﬁcantly different at the
24-week post-treatment assessment (23.5% (12/51) and 30.8%
(16/52), respectively; p¼0.41). At the 48-week post-treatment
assessment, the proportion of patients with HBV DNA
<3400 IU/ml was signiﬁcantly higher in group B than in
group A (30.8% (16/52) and 11.8% (6/51), respectively, p¼0.02;
table 3). Similar patterns of response rates were seen using the
2000 IU/ml HBV DNA cut-off (for 48 weeks post-treatment
28.8% and 11.8%, respectively, p¼0.03), as shown in ﬁgure 3; the
corresponding features for genotype D-infected patients were
27% and 10%, respectively (p¼0.0364). The statistically signiﬁ-
cant differences in virological responses between groups A and B
at 48 weeks post-treatment but not at 24 weeks post-treatment
reﬂected the decline in virological responses in group A (around
50% for HBV DNA <3400 IU/ml and 45% for HBV DNA
<2000 IU/ml) but not in group B during post-treatment follow-
up (ﬁgure 3). Indeed, the proportion of patients who maintained
a virological response at both 24 and 48 weeks post-treatment
was higher in the 96-week treatment group than in the 48-week
treatment group (23% vs 8%, p¼0.05).
HBV DNA was suppressed below 6 IU/ml in 7.7% of patients
(4/52) in group B at both post-treatment assessments; in group
A only one patient had HBV DNA below the limit of detection
and this was only recorded at the 48-week assessment.
Of the patients who achieved HBV DNA <3400 IU/ml at the
end of treatment, 16.1% (5/31) of group A and 42.9% (15/35) of
group B had a sustained response 1 year post-treatment
(p¼0.02). For HBV DNA <2000 IU/ml, these ﬁgures were 16.7%
(5/30) and 40.0% (14/35), respectively (p¼0.04).
None of the group A patients achieved post-treatment HBsAg
clearance or HBsAg levels <10 IU/ml while, in group B, ﬁve
patients had HBsAg <10 IU/ml at the 48-week post-treatment
time point (0% vs 9.6%, p¼0.06) and three cleared HBsAg at the
same time point (0% vs 5.8%, p¼0.24; ﬁgure 4).
By univariate logistic regression analyses, baseline viraemia as
log10 IU/ml (OR 0.634, 95% CI 0.436 to 0.924; p¼0.0177) and
a 96-week course of PegIFN (OR 3.041; 95% CI 1.073 to 8.618,
p¼0.0364) were associated with HBV DNA <2000 IU/ml at
Table 1 Baseline characteristics of patients stratified according to treatment regime
48-week PegIFN
(group A, N[51)
96-week PegIFN
(group B, N[52)
PegIFN + lamivudine
(group C, N[25) p Value* (A vs B)
Male sex, n (%) 33 (65) 45 (87) 18 (72) 0.0098y
Mean6SD age, years 45610.2 44610.4 4668.6 0.6438z
Mean6SD BMI, kg/m2 26.664.7 25.663.7 26.462.9 0.1979z
HBV genotype, n (%)
D 48 (94.1) 48 (92.3) 24 (96.0) 0.7152y
Other 3 (5.9) 4 (7.7) 1 (4.0)
Ishak score 5/6, n (%) 5 (9.8) 7 (13.5) 4 (16.0) 0.5629y
Median (range) standardisedx ALT (IU/l) 119 (34e897) 146 (51e897) 161 (34e897) 0.0634{
Median (range) HBV DNA (log10 IU/ml) 6.1 (2.1e>8.0) 6.0 (2.6e>8.0) 6.2 (3.5e>8.0) 0.9135{
Median (range) HBsAg (IU/ml) 5444 (300e142 744) 5271 (73e32 516) 6825 (669e37 031) 0.6452{
*48-week vs 96-week PegIFN.
yAsymptotic Pearson c2 test.
zTwo-sided t test with unequal variances.
xStandardised ALT to 55 IU/l.
{Two-sided Wilcoxon test with t approximation.
ALT, alanine aminotransferase; BMI, body mass index; HBV DNA, hepatitis B virus DNA; HBsAg, hepatitis B surface antigen; PegIFN, peginterferon a-2a.
Figure 2 Changes in HBV DNA levels in patients treated for 48 (group
A) or 96 (Group B) weeks with pegylated interferon a2a (intention-to-
treat analysis).
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48 weeks post-treatment. Baseline viraemia as log10 IU/ml (OR
0.602, 95% CI 0.404 to 0.896; p¼0.0124) and a 96-week course of
PegIFN (OR 3.608; 95% CI 1.202 to 10.829, p¼0.0221) predicted
a sustained virological response also in a multivariate logistic
regression analysis. The same two variables (baseline HBV DNA
and a 96-week course of PegIFN) were associated with a sustained
virological response deﬁned as HBV DNA <3400 IU/ml. For
the combined endpoint (ie, HBV DNA <3400 IU/ml and normal
ALT levels), the multivariate logistic regression model included
HBV DNA as log10 IU/ml (OR 0.702, 95% CI 0.474 to 1.041;
p¼0.078) and a 96-week course of PegIFN (OR 2.460, 95% CI
0.824 to 7.342; p¼0.1067).
When on-treatment viraemia and serology were considered,
HBV DNA levels as log10 IU/ml at week 12 (OR 0.739; 95% CI
0.555 to 0.983; p¼0.0381) and at week 24 (OR 0.721; 95% CI
0.525 to 0.990; p¼0.0429), HBsAg levels as log10 IU/ml at week 12
(OR 0.267; 95% CI 0.102 to 0.700; p¼0.0073) and at week 24 (OR
0.251; 95% CI 0.107 to 0.588; p¼0.0014) and HBsAg decline as
log10 IU/ml drop at week 24 (OR 4.739; 95% CI 1.496 to 15.014;
p¼0.0082) predicted a sustained virological response at week 48
off treatment. By multivariate analysis, HBsAg levels at week 24
(OR 0.222; 95% CI 0.092 to 0.536; p¼0.0008) and a 96-week
course of PegIFN (OR 4.275, 95% CI 1.263 to 14.470; p¼0.0195)
were the only predictors of a response.
Patients treated with PegIFN plus lamivudine (group C)
In patients in group C the ﬁrst 48 weeks of combination therapy
resulted in mean6SD (median) HBV DNA levels of 1.761.0
(1.5) log10 IU/ml, 1.060.6 (0.7) log10 IU/ml, 0.760.2 (0.7) log10
IU/ml and 0.760.5 (0.7) IU/ml at weeks 12, 24, 36 and 48,
respectively. During the subsequent 48 weeks of PegIFN mono-
therapy, HBV DNA levels increased, reaching 2.061.4 (2.1) log10
IU/ml at week 96, but remaining below baseline levels at all
time points. At the end of treatment, 32.0% of patients (8/25)
achieved a combined response (HBV DNA <3400 IU/ml and
ALT normalisation). As far as the virological response is
concerned, the end of therapy response rates were 76.0% (19/25)
for HBV DNA <3400 IU/ml and 72.0% (18/25) for HBV DNA
<2000 IU/ml (table 2). Forty-eight weeks post-treatment, ﬁve
patients (20.0%) had HBV DNA <3400 IU/ml or HBV DNA
<2000 IU/ml. However, only one (12.5%) of the eight patients
with an end-of-treatment response sustained this at both post-
treatment time points. One patient had HBsAg clearance at the
end of treatment and at 24 weeks post-treatment but no
patients had HBsAg clearance at 48 weeks post-treatment. None
of the patients with detectable HBV DNA at week 24 (n¼12) or
at week 48 (n¼19) of treatment tested positive for lamivudine
resistance.
Safety and tolerability
Ten patients (19.6%) in group A, 12 (23.1%) in group B and 8
(32.0%) in group C withdrew from treatment for any reason
(p¼0.81 for the difference between groups A and B). AEs were the
most common reason for early study discontinuation (table 4).
Study medication dose was reduced in 15 patients in group A
(29.4%), seven in group B (13.5%) and nine in group C (36.0%)
(p¼0.0573). The majority of dose reductions were required to
manage AEs, mainly neutropenia (10 patients (20%) in group A, 4
Table 2 Intention-to-treat analysis of the response rates at end of treatment
Outcomes, n (%)
48-week PegIFN
(group A, N[51)
96-week PegIFN
(group B, N[52)
PegIFN+lamivudine
(group C, N[25) p Value* (A vs B)
HBV DNA <3400 IU/ml + ALT normalisation 15 (29.4) 20 (38.5) 8 (32.0) 0.3323y
HBV DNA <20 000 IU/ml + ALT normalisation 17 (33.3) 20 (38.5) 8 (32.0) 0.5876y
ALT normalisation 18 (35.3) 21 (40.4) 10 (40.0) 0.5944y
HBV DNA <20 000 IU/ml 36 (70.6) 36 (69.2) 19 (76.0) 0.8806y
HBV DNA <3400 IU/ml 31 (60.8) 35 (67.3) 19 (76.0) 0.4902y
HBV DNA <2000 IU/ml 30 (58.8) 35 (67.3) 18 (72.0) 0.3723y
HBV DNA <6 IU/mlx 9 (17.6) 16 (30.8) 6 (24.0) 0.1204y
HBsAg clearance 0 (0.0) 1 (1.9) 1 (4.0) 1.000z
*48-week vs 96-week PegIFN.
yAsymptotic Pearson c2 test.
zFisher exact test.
xLimit of detection of the assay.
ALT, alanine aminotransferase; HBV DNA, hepatitis B viral DNA; HBsAg, hepatitis B surface antigen; PegIFN, peginterferon a-2a.
Table 3 Intention-to-treat analysis of the response rates at the end of 48-week post-treatment follow-up
Outcomes, n (%)
48-week PegIFN
(group A, N[51)
96-week PegIFN
(group B, N[52)
PegIFN + lamivudine
(group C, N[25) p Value* (A vs B)
HBV DNA <3400 IU/ml + ALT normalisation 6 (11.8) 13 (25.0) 5 (20.0) 0.0834y
HBV DNA <20 000 IU/ml + ALT normalisation 10 (19.6) 15 (28.9) 6 (24.0) 0.2742y
ALT normalisation 18 (35.3) 18 (34.6) 9 (36.00) 0.9424y
HBV DNA <20 000 IU/ml 12 (23.5) 20 (38.5) 6 (24.0) 0.1016y
HBV DNA <3400 IU/ml 6 (11.8) 16 (30.8) 5 (20.0) 0.0186y
HBV DNA <2000 IU/ml 6 (11.8) 15 (28.8) 5 (20.0) 0.0314y
HBV DNA <6 IU/mlx 1 (2.0) 4 (7.7) 2 (8.0) 0.3627z
HBsAg <10 IU/ml 0 (0.0) 5 (9.6%) 0 (0.0) 0.0565z
HBsAg clearance 0 (0.0) 3 (5.8) 0 (0.0) 0.2427z
*48-week vs 96-week PegIFN.
yAsymptotic Pearson c2 test.
zFisher exact test.
xLimit of detection of the assay.
ALT, alanine aminotransferase; HBV DNA, hepatitis B viral DNA; HBsAg, hepatitis B surface antigen; PegIFN, peginterferon a-2a.
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(7.7%) in group B and 3 (12%) in group C) and/or thrombocy-
topenia (4 patients (8%) in group A, 1 patient (1.9%) in group B).
The number of patients with at least one treatment-related AE
was similar in all treatment groups (table 4; p¼0.80 for compar-
ison between groups A and B). There were no unexpected AEs;
the most commonly reported were those known to be associated
with IFN-based therapy including asthenia, fever, arthralgia/
myalgia and headache (table 4). Mean neutrophil and platelet
counts decreased during treatment in all groups but progressively
returned to baseline levels during the follow-up period.
A total of 17 serious AEs (SAEs) were reported by 16 patients
(p¼0.10 for the comparison between groups A and B). SAEs
were single cases in a variety of body systems and no individual
SAE was reported by more than one patient. Overall, two SAEs
in group A (interstitial lung disease and fever) and two in group
C (Guillain-Barré syndrome and muscular weakness) were
considered as possibly or probably related to study drug.
Treatment was discontinued in all four cases; only the case of
muscular weakness had not resolved by the end of the follow-
up period. All other SAEs were considered to be unrelated to
the study drug or of unknown relationship. One patient in
group A died due to metastatic hepatocellular carcinoma
during the post-treatment follow-up period, which was
considered unrelated to the study treatment. The majority of
the AEs (78%), treatment-related events (81%), SAEs (70%)
and premature discontinuations (58%) occurred during the ﬁrst
year of PegIFN administration.
DISCUSSION
This study is proof of the concept that, in HBeAg-negative
patients with chronic hepatitis B, a 96-week course with PegIFN
results in better clinical beneﬁts than a 48-week course of similar
treatment and that combined treatment with lamivudine has no
added value. Indeed, more than twice as many patients receiving
extended treatment with PegIFN achieved the endpoint of HBV
DNA <3400 IU/ml plus ALT normalisation 48 weeks post-
treatment, an outcome that was reinforced by the signiﬁcantly
higher proportion of patients achieving <3400 IU/ml HBV DNA
(30.8% vs 11.8%) and <2000 IU/ml HBV DNA (28.8% vs
11.8%). Moreover, the few patients who had a serum HBsAg
decline to <10 IU/ml or who achieved HBsAg clearance
belonged to the extended treatment arm only.
The differences in treatment outcome between arms are the
consequences of the fact that the response rates of the 96-week
treatment arm remained stable during the follow-up period
whereas those of the 48-week treatment declined between
weeks 24 and 48 post-treatment as a consequence of a higher
rate of hepatitis relapses (0% vs 45%). This is not a trivial point
considering that, in the registration trial, a 48-week course of
PegIFN in HBeAg-negative patients with other than genotype D
yielded rates of sustained virological response of 40% at the 24-
week post-treatment time point compared with 20% response
rates in the difﬁcult to cure genotype D subpopulation.8 15 We
also found low rates of virological response at 24-week follow-
up, which further fell at week 48 of post-treatment follow-up
(10%). Conversely, extended treatment with PegIFN led to an
incremental beneﬁt in these difﬁcult to cure patients by causing
a virological response rate of 29% at 48 weeks post-treatment,
which was the consequence of a signiﬁcant reduction in hepa-
titis relapse during follow-up.16
The clinical beneﬁts of extended treatment with PegIFN did
not translate into higher rates of suppressed HBV DNA only but
included increased rates of off-therapy HBsAg clearance, from
2% at the end of treatment to 6% at 48 weeks post-treatment.
An added value of extended therapy were the two additional
patients who showed <10 IU/ml serum levels of HBsAg at
48 weeks post-treatment, a cut-off previously shown to predict
HBsAg clearance in the post-treatment period.17 Circumstantial
evidence indicates that the 6% rate of HBsAg clearance observed
48 weeks after stopping a 96-week course of PegIFN is encour-
aging. In fact, the registration trial of PegIFN in HBeAg-negative
patients had already reported a sixfold increase in the rate of
HBsAg clearance throughout 5 years of post-treatment follow-
up, particularly among responders with <2000 IU/ml HBV
DNA at the end of therapy (28% clearance of HBsAg).18 In our
study, the 29% of patients who achieved <2000 IU/ml HBV
DNA levels 48 weeks post-treatment following extended
therapy with PegIFN might therefore experience additional
beneﬁts such as further clearance of serum HBsAg at any time
point during post-treatment follow-up.
The clinical beneﬁts of the extended treatment regimen are
conﬁrmed by the multivariate analysis where it appeared as an
independent predictor of favourable outcome of HBV therapy.
We acknowledge, however, that the clinical beneﬁts of extended
therapy with PegIFN need to be validated by both powered
studies and ﬁeld practice. The major caveat of our study was the
smaller than planned patient population which was caused by
the patient enrolment process being delayed by a strong
competition with PegIFN that became commercially available in
Figure 4 HBsAg response rates at the end of treatment and 48 weeks
post-treatment in patients treated for 48 (group A) or 96 (Group B)
weeks with pegylated interferon a2a (intention-to-treat analysis).
Figure 3 Virological response rates (HBV DNA <2000 IU/ml) after 24
or 48 weeks of post-treatment follow-up in patients treated for 48 (group
A) or 96 (Group B) weeks with pegylated interferon a2a (intention-to-
treat analysis).
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Italy concurrently with the trial onset. When we designed the
present study we thought interesting to explore whether
a combination of PegIFN with the rapidly acting anti-HBV oral
agent lamivudine had any added value on the assumption that
combination therapy could improve the outcome of the anti-
HBV therapy. On the other hand, pragmatic studies in the ﬁeld
are deemed necessary to assess treatment effectiveness as it
results from patient adherence, compliance and response to
therapy. The strict criteria of our study led to the enrolment of
only a few patients with cirrhosis (16% with combined Ishak
ﬁbrosis score 5 and 6) or complications related to the metabolic
syndrome, both of which are known to limit the access,
adherence and response to IFN-based therapies.8
Notwithstanding differences with previous trials exploring
the efﬁcacy of combined PegIFN and lamivudine for 48 weeks,8
we could not demonstrate any beneﬁt with combination
therapy in our patients who were given 135 mg PegIFN weekly
for an additional 48 weeks after 48 weeks of combination
therapy. Even though this exploratory group was not sufﬁciently
powered with only 25 patients enrolled, combination-treated
patients achieved comparable beneﬁts in terms of end-of-
treatment HBV DNA suppression to those treated for 96 weeks.
We acknowledge, however, that the strategy of combination
therapy in HBeAg-negative patients needs to be reassessed in
light of the more potent third-generation nucleos(t)ide analogs
that have become available in the last few years and new
schemes of combination therapy.5 6
Additional endpoints of our study were tolerability and safety
of extended treatment with PegIFN beyond 48 weeks, for which
there are data in the hepatitis C population only.19 Indeed,
extended treatment with PegIFN was generally well tolerated,
causing no increase in the withdrawal rates compared with the
Table 4 Numbers of patients reporting AEs and laboratory abnormalities
Outcomes, n (%)
48-week PegIFN
(group A, N[51)
96-week PegIFN
(group B, N[52)
PegIFN + lamivudine
(group C, N[25) p Value* (A vs B)
One or more treatment-related AE 42 (82.4) 41 (78.8) 20 (80.0) 0.8041
One or more SAE 8 (15.7) 3 (5.8) 6 (24.0) 0.1222
Deaths 1y 0 0 0.4951
Most common AEsz
Fever 19 (37.3) 19 (36.5) 8 (32.0) 1.000
Asthenia 17 (33.3) 19 (36.5) 11 (44.0) 0.6661
Flu-like symptoms 9 (17.6) 10 (19.2) 4 (16.0) 0.7997
Headache 13 (25.5) 8 (15.4) 7 (28.0) 0.3173
Myalgia 7 (13.7) 8 (15.4) 4 (16.0) 0.7830
Arthralgia 6 (11.8) 6 (11.5) 3 (12.0) 1.000
Back pain 3 (5.9) 6 (11.5) 2 (8.0) 0.3141
Muscular weakness 0 0 2 (8.0) NA
Nausea 5 (9.8) 2 (3.8) 2 (8.0) 0.4336
Abdominal pain 4 (7.8) 4 (7.7) 3 (12.0) 1.000
Diarrhoea 1 (2.0) 3 (5.8) 2 (8.0) 0.3604
Dyspepsia 1 (2.0) 4 (7.7) 2 (8.0) 0.2024
Anxiety 4 (7.8) 5 (9.6) 2 (8.0) 0.7387
Insomnia 4 (7.8) 0 2 (8.0) 0.1164
Irritability 0 3 (5.8) 2 (8.0) 0.1164
Nervousness 0 3 (5.8) 1 (4.0) 0.1164
Pruritus 5 (9.8) 6 (11.5) 3 (12.0) 0.7574
Alopecia 3 (5.9) 3 (5.8) 1 (4.0) 1.000
Urticaria 1 (2.0) 1 (1.9) 2 (8.0) 1.000
Psoriasis 0 3 (5.8) 0 0.1164
Sciatica 1 (2.0) 3 (5.8) 0 0.3604
Pharyngitis 3 (5.9) 2 (3.8) 0 1.000
Urinary tract infection 3 (5.9) 1 (1.9) 0 0.6162
Tooth abscess 0 1 (1.9) 2 (8.0) 0.4943
Cough 3 (5.9) 6 (11.5) 0 0.3141
Anorexia 2 (3.9) 6 (11.5) 0 0.1567
Hypertension 1 (2.0) 4 (7.7) 0 0.2024
Vertigo 1 (2.0) 1 (1.9) 2 (8.0) 1.000
Laboratory abnormalities
ALT increased 3 (5.9) 8 (15.4) 4 (16.0) 0.2008
Neutropenia 12 (23.5) 9 (17.3) 3 (12.0) 0.4719
Thrombocytopenia 6 (11.8) 6 (11.5) 1 (4.0) 1.000
Anaemia 5 (9.8) 4 (7.7) 1 (4.0) 0.7412
Dose modification 15 (29.4) 7 (13.5) 9 (36.0) 0.0573
Discontinuation
Overall 10 (19.6) 12 (23.1) 8 (32.0) 0.8107
Due to AEs 8 (15.7) 6 (11.5) 6 (24.0) 0.2043
Patients may have more than one AE.
*Two-sided Fisher exact test, 48-week vs 96-week PegIFN.
yMetastatic hepatocellular carcinoma during follow-up.
zReported by at least 5% of patients in one of the treatment groups between first study dose up to 8 weeks after therapy.
AE, adverse event; ALT, alanine aminotransferase; PegIFN, peginterferon a-2a; SAE, serious adverse event.
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48-week treatment course and no unexpected AEs. Overall, only
12% of patients treated for 96 weeks withdrew from therapy
due to AEs, apparently fewer than the 25% reported in compa-
rable patients receiving long-term treatment with standard
IFN.12 13 Two patients withdrew from treatment, one as
a consequence of severe interstitial lung disease, a class-related
AE that recently led to the interruption of the clinical develop-
ment of IFN fused with human albumin, and the other due to
muscle weakness previously reported in patients receiving
PegIFN associated with telbivudine.20 The patient with respi-
ratory complications had fully recovered by the end of the
follow-up period but the patient who experienced muscle
weakness during combination therapy did not. We acknowledge
that our choice of injecting a lower weekly dose of 135 mg for the
extension period, which was dictated by the lack of available
safety data on extending the 180 mg weekly dose of PegIFN
beyond the canonical 48 weeks, could have favourably impacted
on the safety of anti-HBV therapy.
In conclusion, this study suggests that extended treatment
with PegIFN to 96 weeks safely improves sustained virological
responses in HBeAg-negative genotype D patients compared
with the current standard of care of 48 weeks.
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